The renin-angiotensin system in the twenty-first century

Blood Pressure

Volumn 10, Issue 5-6, 2001, Pages 327-343

  Nicholls, M Gary ^a   Robertson, J Ian S ^a   Inagami, Tadashi ^a  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; AMRINONE; ANGIOTENSIN; ANGIOTENSIN I; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; NIFEDIPINE; PRAZOSIN; PRORENIN; RECEPTOR SUBTYPE; RENIN; VASOPRESSIN;

ADRENAL CORTEX ADENOMA; ADRENERGIC SYSTEM; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ATHEROGENESIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; COUGHING; DRUG CONTRAINDICATION; ESSENTIAL HYPERTENSION; FEMALE; HEART VENTRICLE HYPERTROPHY; HORMONE RELEASE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PLASMA RENIN ACTIVITY; PREGNANCY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN RELEASE; RENOVASCULAR HYPERTENSION; REVIEW; TISSUE DISTRIBUTION; VASOCONSTRICTION; CARDIOVASCULAR DISEASE; DRUG EFFECT; MALE; PHYSIOLOGY;

ADRENOCORTICAL ADENOMA; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYPERTENSION, RENAL; MALE; PREGNANCY; RENIN-ANGIOTENSIN SYSTEM;

EID: 0035527573     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/080370501753400638     Document Type: Review

References (124)

1. The Renin-angiotensin system
2. The renin-angiotensin system in the year 2000
3. Epidemiology of the renin-angiotensin system in hypertension
4. Intracellular action of renin angiotensin production and release
5. Intracardiac detection of angiotensinogen and renin: A localized renin-angiotensin system in neonatal rat heart
6. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro
7. Identification of three human renin mRNA isoforms from alternative tissue-specific transcriptional initiation
8. Roles of renal and vascular renin in spontaneous hypertension and switching of the mechanism upon nephrectomy: Lack of hypotensive effects of inhibitors of renin, converting enzyme and angiotensin II receptor nephrectomy
9. Prorenin, renin, angiotensinogen and angiotensin converting enzyme in normal and failing human hearts. Evidence for renin-binding
10. Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen
11. The renin-angiotensin system
12. Identification of angiotensin receptor subtypes
13. The angiotensin II receptors
14. A
15. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor
16. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition
17. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors
18. Molecular biology of angiotensin II receptors: An overview
19. Identification of two subtypes in the rat type 1 angiotensin II receptor
20. Cloning and expression of a novel angiotensin II receptor subtype
21. Angiotensin II type-1 receptor subtype cDNAs: Differential tissue expression and hormonal regulation
22. Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells
23. Angiotensin II signal transduction in vascular smooth muscle: Role of tyrosine kinases
24. The importance of tyrosine phosphorylation in angiotensin II signaling
25. Angiotensin II signaling in vascular smooth muscle. New Concepts
26. Signal transduction of angiotensin II type 1 receptor through receptor tyrosine kinase
27. Signal transduction mechanism mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells
28. Effectively targeting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: Rationale for using angiotensin II blockers in combination with angiotensin-converting enzyme inhibitors
29. Combined treatment of severe intractable hypertension with captopril and diuretic
30. Converting-enzyme inhibitor enalapril in treatment of hypertension with renal artery stenosis
31. Enalapril in treatment of hypertension with renal artery stenosis: Changes in 33 blood pressure, renin, angiotensin I and II, renal function, and body composition
32. Angiotensin II receptor antagonists: Losartan, valsartan, irbesartan, and candesartan
33. Targeting of the renin-angiotensin system by antisense gene therapy: A possible strategy for the long-term control of hypertension
34. The future of hypertension therapy: Sense, antisense, or nonsense?
35. Knockout of renin-angiotensin system genes: Effects on vascular development
36. Renin relationships in congestive cardiac failure, treated and untreated
37. Correction of dilutional hyponatremia in severe chronic heart failure by converting-enzyme inhibition
38. Total body electrolyte composition in patients with heart failure: A comparison with normal subjects and patients with untreated hypertension
39. Hyponatremic-hypertensive syndrome with renal ischemia. An underrecognized disorder
40. Cautions over the current epidemic of primary aldosteronism
41. Cautions over idiopathic aldosteronism
42. Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11 82
43. Idiopathic aldosteronism: A diagnostic artifact?
44. The myth of idiopathic aldosteronism
45. Response of aldosterone and 18-hydroxycorticosterone to angiotensin II in normal man and patients with essential hypertension, Conn's syndrome, and non-tumorous hyperaldosteronism
46. Hypertension with aldosterone excess and low plasma-renin: Preoperative distinction between patients with and without adrenocortical tumour
47. Clinical, biochemical, and pathological features of low-renin ("primary") hyperaldosteronism
48. Primary aldosterone excess: Conn's syndrome and similar disorders
49. Quadric analysis in the preoperative distinction between patients with and without adrenocortical tumors in hypertension with aldosterone excess and low plasma renin
50. Similarity of idiopathic aldosteronism and essential hypertension: A statistical comparison
51. Low-renin ("primary") hyperaldosteronism: Differential diagnosis and distinction of subgroups within the syndrome
52. The treatment of low renin ("primary") hyperaldosteronism
53. Combined captopril and spironolactone treatment in Conn's syndrome with renal impairment and refractory hypertension
54. Efficacy of an angiotensin II receptor antagonist in managing hyperaldosteronism
55. The epidemiology of plasma renin
56. Plasma renin activity and ischemic heart disease
57. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension
58. Low urinary sodium is associated with greater risk of myocardial infarction among treated hypertensive men
59. Dietary sodium intake and mortality: The National Health and Nutrition Survey (NHANES I)
60. Renin-sodium profile and the risk of myocardial infarction in patients with hypertension
61. Low urinary sodium and myocardial infarction
62. Sodium intake and mortality
63. Dietary sodium intake and mortality: NHANES
64. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
65. Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice
66. Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling
67. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan
68. 2+ -dependent signaling
69. Identification of an essential signaling cascade for mitogen activated protein kinase activation of angiotensin II in cultured vascular smooth muscle cells
70. Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen activated protein kinase activation in vascular smooth muscle cells
71. 2+/calmodulin-dependent transactivation of epidermal growth factor receptor
72. Active oxygen species stimulate vascular smooth muscle cell growth and proto oncogen expression
73. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells
74. IA cells. Cross-talk between angiotensin II and interleukin-6 nuclear signaling
75. 1 receptor
76. Pathophysiological roles of angiotensin II type 2 receptor in cardiovascular and renal diseases
77. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system
78. Dual effect of angiotensin type 2 receptor on cardiovascular hypertrophy
79. Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload
80. Emerging treatments for hypertension: Potential role for vasopeptidase inhibition
81. He clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure
82. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial
83. Vasopeptidase inhibition and angio-oedema
84. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial
85. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study
86. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?
87. Calcium channel blockers, ACE inhibitors, and the risk of cancer in hypertensive patients
88. Reduction of risk of pneumonia associated with use of angiotensin I converting enzyme inhibitors in elderly patients
89. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study
90. Dual blockade of renin-angiotensin system
91. Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2) 27 rat
92. Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes
93. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes
94. Modulation of the renin-angiotensin system and retinopathy
95. Effect of angiotensin-converting enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: Randomised double-blind controlled trial
96. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
97. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial -the Losartan Heart Failure Survival Study ELITE II
98. Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease
99. Role of chymase on vascular proliferation
100. Losartan and fetal toxic effects
101. Angiotensin-II-receptors in pregnancy
102. Fetal toxic effects and angiotensin-II-receptor antagonists
103. Role of endothelin and isoprostanes in slow pressor responses to angiotensin II
104. Angiotensin II stimulates synthesis of endothelial nitric oxide synthase
105. Gene transfers of endothelial nitric oxide synthase reduces angiotensin 11-induced endothelial dysfunction
106. Effect of nitric oxide on DNA replication induced by angiotensin II in rat cardiac fibroblasts
107. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: Evidence for involvement of the renin-angiotensin system
108. Tissue angiotensin and pathobiology of vascular disease. A unifying hypothesis
109. Effects of ramipril and vitamin E on atherosclerosis. The Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and Vitamin E (SECURE)
110. Haplotypes of the human renin gene associated with essential hypertension and stroke
111. Angiotensinogen (M235T) and angiotensin-converting enzyme (I/D) polymorphisms in association with plasma renin and prorenin levels
112. Even lessons from two candidate genes in human essential hypertension: Angiotensinogen and epithelial sodium channel
113. Angiotensin-converting enzyme insertion-deletion polymorphism in normotensive and pre-eclamptic pregnancies
114. Carotid thickening, cardiac hypertrophy, and angiotensin converting enzyme gene polymorphism in patients with hypertension
115. Gene polymorphism of the renin-angiotensin system associates with risk for lacunar infarction: The Osahama study
116. Confirmation needed for genes for hypertension
117. Lack of association between a biallelic polymorphism in the adducin gene in whites and African Americans
118. Association and linkage analysis of the α-adducin gene and blood pressure
119. Lack of evidence of an association between α-adducin and blood pressure in Asian populations
120. Association between the α-adducin gene and hypertension in the HyperGEN study
121. Association and linkage analysis of α-adducin polymorphism: Is the glass half full or half empty?
122. Hypertension as a complex trait amenable to genetic analysis: Basic strategies and integrative approaches
123. Angiotensin II, aldosterone and arterial pressure: A quantitative approach. Arthur C Corcoran Memorial Lecture by Robertson JIS
124. Ca) channels